Related Experiment Video

Updated: Feb 26, 2026

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

4.6K

Increased bone matrix mineralization in treatment-naïve children with inflammatory bowel disease

Barbara M Misof1, Paul Roschger1, Klaus Klaushofer1

  • 1Ludwig Boltzmann-Institute of Osteology at Hanusch-Hospital of WGKK & Trauma Centre Meidling of AUVA, 1st Medical Department, Hanusch-Hospital, Vienna, Austria.

Bone
|July 15, 2017
PubMed

Insights

Children with new inflammatory bowel disease (IBD) show altered bone mineralization, with higher calcium levels and lower bone turnover. This suggests compromised bone strength in pediatric IBD patients at diagnosis.

Area of Science:

  • Pediatric Bone Metabolism
  • Inflammatory Bowel Disease Pathophysiology
  • Skeletal Complications in Chronic Illness

Background:

  • Inflammatory bowel disease (IBD) impacts multiple organ systems, notably the skeleton.
  • Children with IBD often exhibit reduced bone mineral density (BMD) and bone turnover.
  • Bone mineralization density distribution (BMDD) alterations are linked to bone material strength but are understudied in pediatric chronic inflammatory conditions.

Purpose of the Study:

  • To characterize BMDD in treatment-naïve pediatric IBD patients using quantitative backscatter electron imaging.
  • To compare BMDD in pediatric IBD patients with healthy pediatric reference data.
  • To analyze correlations between BMDD and biochemical/histomorphometric markers of bone turnover.

Main Methods:

  • Trans-iliac bone biopsy samples were analyzed from 20 treatment-naïve children diagnosed with IBD.
  • Quantitative backscatter electron imaging was used to assess BMDD in cancellous and cortical bone compartments.
  • BMDD outcomes were compared to pediatric reference data and correlated with serum alkaline phosphatase (ALP), bone-specific alkaline phosphatase (bsALP), and urinary crosslinked N-telopeptide of type I collagen (uNTX).

Main Results:

  • IBD patients exhibited a shift in BMDD towards higher calcium concentrations compared to controls.
  • Increased most frequent calcium concentration (Cn.CaPeak) and highly mineralized bone (Cn.CaHigh) were observed in cancellous bone.
  • Cortical bone showed increased mineralization heterogeneity (Ct.CaWidth) and highly mineralized bone (Ct.CaHigh).
  • Higher bone matrix calcium concentrations (CaMean, CaPeak, CaHigh) correlated with lower levels of ALP, bsALP, and uNTX, indicating decreased bone turnover.

Conclusions:

  • Treatment-naïve pediatric IBD patients demonstrate decreased bone turnover.
  • This leads to increased bone matrix mineralization density, potentially compromising bone strength.
  • BMDD characterization provides insights into skeletal fragility in pediatric IBD.

Keywords:
Bone biopsyBone mineralizationChildrenInflammatory bowel diseaseOsteoporosis

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K
Improved Methodology for Studying Postnatal Osteogenesis via Intramembranous Ossification in a Murine Bone Marrow Injury Model05:10

Improved Methodology for Studying Postnatal Osteogenesis via Intramembranous Ossification in a Murine Bone Marrow Injury Model

Published on: February 7, 2025

765

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
972
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
852
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
652
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
573